• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三维肝类器官中肝星状细胞的差异纤维化表型。

Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids.

机构信息

Wake Forest School of Medicine, Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.

School of Medicine, Meharry Medical College, Nashville, Tennessee.

出版信息

Biotechnol Bioeng. 2020 Aug;117(8):2516-2526. doi: 10.1002/bit.27379. Epub 2020 May 23.

DOI:10.1002/bit.27379
PMID:32391915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7370813/
Abstract

Liver fibrosis occurs in most cases of chronic liver disease, which are somewhat common, but also a potentially deadly group of diseases. In vitro modeling of liver fibrosis relies primarily on the isolation of in vivo activated hepatic stellate cells (aHSCs) and studying them in standard tissue culture dishes (two-dimensional [2D]). In contrast, modeling of fibrosis in a biofabricated three-dimensional (3D) construct allows us to study changes to the environment, such as extracellular matrix (ECM) composition and structure, and tissue rigidity. In the current study, we used aHSCs produced through subcultures in 2D and encapsulated them in a 3D collagen gel to form spherical constructs. In parallel, and as a comparison, we used an established HSC line, LX-2, representing early and less severe fibrosis. Compared with LX-2 cells, the aHSCs created a stiffer environment and expressed higher levels of TIMP1 and LOXL2, all of which are indicative of advanced liver fibrosis. Collectively, this study presents a fibrosis model that could be incorporated with multi-cellular models to more accurately reflect the effects of a severe fibrotic environment on liver function.

摘要

肝纤维化发生于大多数慢性肝病,这些疾病较为常见,但也是一组潜在致命的疾病。体外肝纤维化模型主要依赖于体内激活的肝星状细胞(aHSCs)的分离,并在标准组织培养皿(二维 [2D])中对其进行研究。相比之下,生物制造的三维(3D)构建体中的纤维化模型使我们能够研究环境的变化,如细胞外基质(ECM)的组成和结构以及组织硬度。在本研究中,我们使用通过 2D 传代培养产生的 aHSCs,并将其包裹在 3D 胶原凝胶中形成球形构建体。同时,作为比较,我们使用了一个已建立的 HSC 系 LX-2,代表早期和较轻的纤维化。与 LX-2 细胞相比,aHSCs 创造了一个更硬的环境,并表达了更高水平的 TIMP1 和 LOXL2,所有这些都表明存在晚期肝纤维化。总的来说,这项研究提出了一种纤维化模型,可以与多细胞模型结合使用,以更准确地反映严重纤维化环境对肝功能的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/c9b3e1392493/nihms-1603516-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/1112e94bab25/nihms-1603516-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/d9efb87094f6/nihms-1603516-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/d2374213b698/nihms-1603516-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/3d4c3bb4c92c/nihms-1603516-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/bb96b3a3b114/nihms-1603516-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/c9b3e1392493/nihms-1603516-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/1112e94bab25/nihms-1603516-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/d9efb87094f6/nihms-1603516-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/d2374213b698/nihms-1603516-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/3d4c3bb4c92c/nihms-1603516-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/bb96b3a3b114/nihms-1603516-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b4f/7370813/c9b3e1392493/nihms-1603516-f0006.jpg

相似文献

1
Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids.三维肝类器官中肝星状细胞的差异纤维化表型。
Biotechnol Bioeng. 2020 Aug;117(8):2516-2526. doi: 10.1002/bit.27379. Epub 2020 May 23.
2
PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis.PDGFRβ 靶向 TRAIL 特异性诱导活化的肝星状细胞凋亡并改善肝纤维化。
Apoptosis. 2020 Feb;25(1-2):105-119. doi: 10.1007/s10495-019-01583-3.
3
Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.胶原酶 I 修饰的共递送胶束增强细胞外基质降解和肝星状细胞靶向治疗肝纤维化。
Acta Biomater. 2022 Oct 15;152:235-254. doi: 10.1016/j.actbio.2022.08.065. Epub 2022 Sep 8.
4
Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation.含III型纤连蛋白结构域蛋白5通过抑制肝星状细胞激活减轻肝纤维化
Cell Physiol Biochem. 2018;48(1):227-236. doi: 10.1159/000491722. Epub 2018 Jul 13.
5
Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis.促纤维化化合物在人肝纤维化三维多细胞模型中诱导星状细胞活化、细胞外基质重塑和Nrf2活化。
PLoS One. 2017 Jun 30;12(6):e0179995. doi: 10.1371/journal.pone.0179995. eCollection 2017.
6
Multi-cellular transitional organotypic models to investigate liver fibrosis.用于研究肝纤维化的多细胞过渡型器官型模型。
Acta Biomater. 2018 Dec;82:79-92. doi: 10.1016/j.actbio.2018.10.010. Epub 2018 Oct 11.
7
Molecular Mechanism Responsible for Fibronectin-controlled Alterations in Matrix Stiffness in Advanced Chronic Liver Fibrogenesis.晚期慢性肝纤维化中纤连蛋白控制基质硬度改变的分子机制
J Biol Chem. 2016 Jan 1;291(1):72-88. doi: 10.1074/jbc.M115.691519. Epub 2015 Nov 9.
8
Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver.细胞外基质蛋白质组学分析肝星状细胞系 LX-2 鉴定细胞因子 CYR61 和 Wnt-5a 为纤维性肝病的新成分。
J Proteome Res. 2012 Aug 3;11(8):4052-64. doi: 10.1021/pr3000927. Epub 2012 Jun 28.
9
Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages.使用肝细胞、原代肝窦内皮细胞、肝星状细胞和巨噬细胞生成肝纤维化类器官。
Cells. 2023 Oct 24;12(21):2514. doi: 10.3390/cells12212514.
10
Biofabricated 3D in vitro model of fibrosis-induced abnormal hepatoblast/biliary progenitors' expansion of the developing liver.生物制造的发育中肝脏纤维化诱导的成肝细胞/胆管祖细胞异常扩增的三维体外模型。
Bioeng Transl Med. 2021 Jun 5;6(3):e10207. doi: 10.1002/btm2.10207. eCollection 2021 Sep.

引用本文的文献

1
Mesenchymal stem cell-derived extracellular vesicles attenuate periductal fibrosis by inhibiting Th17 differentiation in human liver multilineage organoids and Mdr2 mice.间充质干细胞衍生的细胞外囊泡通过抑制人肝脏多谱系类器官和Mdr2小鼠中的Th17分化来减轻导管周围纤维化。
J Nanobiotechnology. 2025 Jul 28;23(1):546. doi: 10.1186/s12951-025-03617-2.
2
Challenges of modelling of liver fibrosis.肝纤维化建模的挑战。
Front Cell Dev Biol. 2025 Apr 30;13:1567916. doi: 10.3389/fcell.2025.1567916. eCollection 2025.
3
Recent Advances in Three-Dimensional In Vitro Models for Studies of Liver Fibrosis.

本文引用的文献

1
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities.慢性肝病中的肝纤维化:诊断和治疗方式的最新进展。
Drugs. 2019 Jun;79(9):903-927. doi: 10.1007/s40265-019-01126-9.
2
Fiber alignment drives changes in architectural and mechanical features in collagen matrices.纤维排列驱动胶原蛋白基质中结构和力学性质的改变。
PLoS One. 2019 May 15;14(5):e0216537. doi: 10.1371/journal.pone.0216537. eCollection 2019.
3
Alcoholic liver disease: Utility of animal models.酒精性肝病:动物模型的应用。
用于肝纤维化研究的三维体外模型的最新进展
Tissue Eng Regen Med. 2025 May 13. doi: 10.1007/s13770-025-00719-8.
4
Advances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling.肝脏类器官的进展:复制肝脏复杂性用于毒性评估和疾病建模。
Stem Cell Res Ther. 2025 Jan 26;16(1):27. doi: 10.1186/s13287-025-04139-2.
5
Beyond bone volume: Understanding tissue-level quality in healing of maxillary vs. femoral defects.超越骨量:理解上颌与股骨缺损愈合中的组织水平质量。
Acta Biomater. 2024 Oct 1;187:409-421. doi: 10.1016/j.actbio.2024.08.042. Epub 2024 Aug 28.
6
Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues.基于具有特定刚度的细胞外基质构建的二维血管化肝脏类器官,用于模拟纤维化组织和正常组织。
J Tissue Eng. 2024 Aug 10;15:20417314241268344. doi: 10.1177/20417314241268344. eCollection 2024 Jan-Dec.
7
The impact of matrix stiffness on hepatic cell function, liver fibrosis, and hepatocellular carcinoma-Based on quantitative data.基于定量数据的基质硬度对肝细胞功能、肝纤维化和肝细胞癌的影响
Biophys Rev (Melville). 2024 Jun 3;5(2):021306. doi: 10.1063/5.0197875. eCollection 2024 Jun.
8
Liver organoid culture methods.肝脏类器官培养方法。
Cell Biosci. 2023 Nov 1;13(1):197. doi: 10.1186/s13578-023-01136-x.
9
The Current Proceedings of PSC-Based Liver Fibrosis Therapy.基于PSC的肝纤维化治疗的当前进展
Stem Cell Rev Rep. 2023 Oct;19(7):2155-2165. doi: 10.1007/s12015-023-10592-4. Epub 2023 Jul 25.
10
Multicellular Liver Organoids: Generation and Importance of Diverse Specialized Cellular Components.多细胞肝类器官:多样化特化细胞组分的生成与重要性。
Cells. 2023 May 19;12(10):1429. doi: 10.3390/cells12101429.
World J Gastroenterol. 2018 Dec 7;24(45):5063-5075. doi: 10.3748/wjg.v24.i45.5063.
4
Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.肝纤维化背景下的癌变:对肝细胞癌治疗的启示。
World J Gastroenterol. 2018 Oct 21;24(39):4436-4447. doi: 10.3748/wjg.v24.i39.4436.
5
Three-Dimensional Cell Culture Models in Drug Discovery and Drug Repositioning.药物发现与药物重新定位中的三维细胞培养模型
Front Pharmacol. 2018 Jan 23;9:6. doi: 10.3389/fphar.2018.00006. eCollection 2018.
6
Risk of liver disease in methotrexate treated patients.甲氨蝶呤治疗患者的肝脏疾病风险。
World J Hepatol. 2017 Sep 18;9(26):1092-1100. doi: 10.4254/wjh.v9.i26.1092.
7
3D in vitro models of liver fibrosis.肝纤维化的 3D 体外模型。
Adv Drug Deliv Rev. 2017 Nov 1;121:133-146. doi: 10.1016/j.addr.2017.07.004. Epub 2017 Jul 8.
8
Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents.肝纤维化的病理生理学和抗纤维化药物研发的方法学障碍。
Adv Drug Deliv Rev. 2017 Nov 1;121:3-8. doi: 10.1016/j.addr.2017.05.016. Epub 2017 Jun 9.
9
Hepatic stellate cells as key target in liver fibrosis.肝星状细胞作为肝纤维化的关键靶点。
Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. doi: 10.1016/j.addr.2017.05.007. Epub 2017 May 12.
10
Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis.小分子介导的肌成纤维细胞转分化抑制用于纤维化治疗
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4679-4684. doi: 10.1073/pnas.1702750114. Epub 2017 Apr 17.